Recursion Pharmaceuticals Stock News

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 9,625 shares of the stock in a transaction that occurred on Tuesday, December 21st. The stock was sold at an average price of $18.75, for a total transaction of $180,468.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available […]

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) traded at $18.91 at close of the session on Tuesday, 12/21/21, made a downward move of -1.97% on its previous days price. Looking at the stock we see that its previous close was $19.29 with the days price range being $18.17 $19.50. In terms of its 52-week price range, RXRX Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) -1.97% Decline Turns Investors Off From Company Stock Read More »

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Larson sold 2,500 shares of the firms stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $18.74, for a total transaction of $46,850.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC [] The post Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 2,500 Shares of Stock appeared first on ETF Daily News .

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Larson sold 2,500 shares of the businesss stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $18.74, for a total transaction of $46,850.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. []

The trading price of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) closed higher on Friday, December 10, closing at $18.98, 0.74% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 1,086 shares of the firms stock in a transaction that occurred on Thursday, December 9th. The shares were sold at an average price of $20.01, for a total transaction of $21,730.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 1,086 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, December 9th. The stock was sold at an average price of $20.01, for a total value of $21,730.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 3,125 shares of the business’s stock in a transaction dated Tuesday, December 7th. The stock was sold at an average price of $20.51, for a total transaction of $64,093.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Shares […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 3,125 shares of the companys stock in a transaction that occurred on Tuesday, December 7th. The stock was sold at an average price of $20.51, for a total transaction of $64,093.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available []

Goldman Sachs Group Inc. acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 11,013 shares of the companys stock, valued at approximately $402,000. A number of other institutional investors also recently added to or reduced []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gapped up prior to trading on Tuesday . The stock had previously closed at $18.48, but opened at $19.72. Recursion Pharmaceuticals shares last traded at $19.74, with a volume of 12,514 shares trading hands. Several equities analysts recently commented on RXRX shares. SVB Leerink dropped their target price on Recursion Pharmaceuticals […]

In the last trading session, 2.08 million Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares changed hands as the companys beta touched 0. With the companys per share price at $18.48 changed hands at $0.76 or 4.29% during last session, the market valuation stood at $3.35B. RXRXs last price was a discount, traded about -131.66% off its 52-week Should You Invest In Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) In 2021? Read More »

The stock price of Recursion (NASDAQ: RXRX) increased by over 12% during intraday trading today. This is why it happened.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX ) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY ). The expanded collaboration will include Recursion''s inferential search capabilities based on its growing maps of human cellular biology. Recursion Full story available on Benzinga.com

Innate Pharma (OTCMKTS:IPHYF) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk. Institutional and Insider Ownership 29.8% of Recursion Pharmaceuticals shares are held by institutional investors. Strong institutional []